$7.39
-0.34-4.40%
At Close: -
$7.38
-0.01-0.14%
After Hours: 4:58 PM EDT
15 minutes delayed
Iovance Biotherapeutics
IOVANASDAQ
Iovance Biotherapeutics (NASDAQ:IOVA) Stock, Analyst Ratings, Price Targets, Predictions
Iovance Biotherapeutics Inc has a consensus price target of $20.71, established from looking at the 79 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., JMP Securities, and HC Wainwright & Co. on June 28, 2024, June 20, 2024, and June 3, 2024. With an average price target of $29 between HC Wainwright & Co., JMP Securities, and HC Wainwright & Co., there's an implied 292.99% upside for Iovance Biotherapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
JMP Securities
Piper Sandler
Truist Securities
Wells Fargo
1calculated from analyst ratings
Analyst Ratings for Iovance Biotherapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/28/2024 | Buy Now | 333.65% | HC Wainwright & Co. | Joseph Pantginis | $32 → $32 | Reiterates | Buy → Buy | Get Alert |
| 06/20/2024 | Buy Now | 211.68% | JMP Securities | Reni Benjamin | $25 → $23 | Maintains | Market Outperform | Get Alert |
| 06/03/2024 | Buy Now | 333.65% | HC Wainwright & Co. | Joseph Pantginis | $32 → $32 | Reiterates | Buy → Buy | Get Alert |
| 05/31/2024 | Buy Now | 333.65% | HC Wainwright & Co. | Joseph Pantginis | $32 → $32 | Reiterates | Buy → Buy | Get Alert |
| 05/24/2024 | Buy Now | 333.65% | HC Wainwright & Co. | Joseph Pantginis | → $32 | Reiterates | Buy → Buy | Get Alert |
| 05/10/2024 | Buy Now | 333.65% | HC Wainwright & Co. | Joseph Pantginis | → $32 | Reiterates | Buy → Buy | Get Alert |
| 03/14/2024 | Buy Now | 157.48% | Piper Sandler | Joseph Catanzaro | $18 → $19 | Maintains | Overweight | Get Alert |
| 03/07/2024 | Buy Now | 252.34% | Truist Securities | Asthika Goonewardene | $17 → $26 | Maintains | Buy | Get Alert |
| 03/04/2024 | Buy Now | 333.65% | HC Wainwright & Co. | Joseph Pantginis | → $32 | Reiterates | Buy → Buy | Get Alert |
| 03/01/2024 | Buy Now | 238.79% | Wells Fargo | Yanan Zhu | $22 → $25 | Maintains | Overweight | Get Alert |
| 02/29/2024 | Buy Now | 333.65% | HC Wainwright & Co. | Joseph Pantginis | → $32 | Reiterates | Buy → Buy | Get Alert |
| 02/29/2024 | Buy Now | 184.58% | Goldman Sachs | Andrea Tan | $19 → $21 | Maintains | Buy | Get Alert |
| 02/29/2024 | Buy Now | 198.13% | Barclays | Peter Lawson | $18 → $22 | Maintains | Overweight | Get Alert |
| 02/21/2024 | Buy Now | 157.48% | Goldman Sachs | Andrea Tan | $13 → $19 | Maintains | Buy | Get Alert |
| 02/20/2024 | Buy Now | 238.79% | JMP Securities | Reni Benjamin | $18 → $25 | Maintains | Market Outperform | Get Alert |
| 02/20/2024 | Buy Now | 198.13% | Wells Fargo | Yanan Zhu | $17 → $22 | Maintains | Overweight | Get Alert |
| 02/20/2024 | Buy Now | 157.48% | Goldman Sachs | Andrea Tan | $13 → $19 | Maintains | Buy | Get Alert |
| 02/20/2024 | Buy Now | 143.93% | Piper Sandler | Joseph Catanzaro | $14 → $18 | Maintains | Overweight | Get Alert |
| 02/20/2024 | Buy Now | 360.75% | Chardan Capital | Geulah Livshits | $29 → $34 | Maintains | Buy | Get Alert |
| 12/27/2023 | Buy Now | 279.44% | HC Wainwright & Co. | Joseph Pantginis | $38 → $28 | Maintains | Buy | Get Alert |
| 12/27/2023 | Buy Now | 130.37% | Truist Securities | Asthika Goonewardene | $17 → $17 | Reiterates | Buy → Buy | Get Alert |
| 11/20/2023 | Buy Now | 62.62% | Goldman Sachs | Andrea Tan | → $12 | Initiates | → Buy | Get Alert |
| 11/08/2023 | Buy Now | 279.44% | HC Wainwright & Co. | Joseph Pantginis | $38 → $28 | Maintains | Buy | Get Alert |
| 09/18/2023 | Buy Now | 143.93% | Barclays | Peter Lawson | $40 → $18 | Maintains | Overweight | Get Alert |
| 09/15/2023 | Buy Now | 130.37% | Truist Securities | Asthika Goonewardene | → $17 | Reiterates | Buy → Buy | Get Alert |
| 09/15/2023 | Buy Now | 306.54% | Mizuho | Mara Goldstein | → $30 | Reiterates | Buy → Buy | Get Alert |
| 09/15/2023 | Buy Now | 238.79% | Stifel | Benjamin Burnett | → $25 | Reiterates | Buy → Buy | Get Alert |
| 09/15/2023 | Buy Now | 143.93% | JMP Securities | Reni Benjamin | → $18 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 09/15/2023 | Buy Now | 414.95% | HC Wainwright & Co. | Joseph Pantginis | → $38 | Reiterates | Buy → Buy | Get Alert |
| 09/13/2023 | Buy Now | 238.79% | Stifel | Benjamin Burnett | $27 → $25 | Maintains | Buy | Get Alert |
| 08/17/2023 | Buy Now | 143.93% | JMP Securities | Reni Benjamin | → $18 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 08/16/2023 | Buy Now | 292.99% | Chardan Capital | Geulah Livshits | $29 → $29 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2023 | Buy Now | 292.99% | Chardan Capital | Geulah Livshits | → $29 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2023 | Buy Now | 414.95% | HC Wainwright & Co. | Joseph Pantginis | → $38 | Reiterates | Buy → Buy | Get Alert |
| 07/11/2023 | Buy Now | 130.37% | Truist Securities | Asthika Goonewardene | → $17 | Reiterates | Buy → Buy | Get Alert |
| 07/11/2023 | Buy Now | 292.99% | Chardan Capital | Geulah Livshits | → $29 | Reiterates | Buy → Buy | Get Alert |
| 07/10/2023 | Buy Now | 414.95% | HC Wainwright & Co. | Joseph Pantginis | → $38 | Reiterates | Buy → Buy | Get Alert |
| 06/27/2023 | Buy Now | 306.54% | Mizuho | Mara Goldstein | → $30 | Reiterates | Buy → Buy | Get Alert |
| 06/16/2023 | Buy Now | 306.54% | Mizuho | Mara Goldstein | → $30 | Reiterates | Buy → Buy | Get Alert |
| 06/15/2023 | Buy Now | 414.95% | HC Wainwright & Co. | Joseph Pantginis | → $38 | Reiterates | Buy → Buy | Get Alert |
| 06/05/2023 | Buy Now | 143.93% | JMP Securities | Reni Benjamin | → $18 | Reiterates | → Market Outperform | Get Alert |
| 05/30/2023 | Buy Now | 130.37% | Wells Fargo | Yanan Zhu | $11 → $17 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 05/30/2023 | Buy Now | 143.93% | JMP Securities | Reni Benjamin | → $18 | Reinstates | Market Outperform → Market Perform | Get Alert |
| 05/30/2023 | Buy Now | 225.23% | Stifel | Benjamin Burnett | $21 → $24 | Maintains | Buy | Get Alert |
| 05/30/2023 | Buy Now | 292.99% | Chardan Capital | Geulah Livshits | → $29 | Reiterates | Buy → Buy | Get Alert |
| 05/30/2023 | Buy Now | 414.95% | HC Wainwright & Co. | Joseph Pantginis | → $38 | Reiterates | Buy → Buy | Get Alert |
| 05/28/2023 | Buy Now | 184.58% | Stifel | Benjamin Burnett | → $21 | Maintains | Buy | Get Alert |
| 05/23/2023 | Buy Now | 211.68% | Baird | Michael Ulz | $20 → $23 | Maintains | Outperform | Get Alert |
| 05/11/2023 | Buy Now | 184.58% | Stifel | Benjamin Burnett | → $21 | Maintains | Buy | Get Alert |
| 05/10/2023 | Buy Now | 171.03% | Baird | Michael Ulz | $25 → $20 | Maintains | Outperform | Get Alert |
| 03/27/2023 | Buy Now | 49.07% | Wells Fargo | Yanan Zhu | → $11 | Assumes | → Equal-Weight | Get Alert |
| 03/27/2023 | Buy Now | 414.95% | HC Wainwright & Co. | Joseph Pantginis | → $38 | Reiterates | → Buy | Get Alert |
| 03/06/2023 | Buy Now | 49.07% | Wells Fargo | Adam Shine | $14 → $11 | Maintains | Equal-Weight | Get Alert |
| 03/01/2023 | Buy Now | 103.27% | Oppenheimer | Mark Breidenbach | $25 → $15 | Maintains | Outperform | Get Alert |
| 03/01/2023 | Buy Now | 292.99% | Chardan Capital | Geulah Livshits | → $29 | Reiterates | → Buy | Get Alert |
| 03/01/2023 | Buy Now | 414.95% | HC Wainwright & Co. | Joseph Pantginis | → $38 | Reiterates | → Buy | Get Alert |
| 01/27/2023 | Buy Now | 89.72% | Piper Sandler | Joseph Catanzaro | $11 → $14 | Upgrade | Neutral → Overweight | Get Alert |
| 01/24/2023 | Buy Now | 130.37% | Truist Securities | Asthika Goonewardene | $16 → $17 | Maintains | Buy | Get Alert |
| 12/09/2022 | Buy Now | -18.69% | Goldman Sachs | Madhu Kumar | $20 → $6 | Downgrade | Buy → Neutral | Get Alert |
| 12/09/2022 | Buy Now | -18.69% | Benchmark | Madhu Kumar | $20 → $6 | Downgrade | Buy → Neutral | Get Alert |
| 11/21/2022 | Buy Now | 184.58% | JMP Securities | Reni Benjamin | $25 → $21 | Maintains | Market Outperform | Get Alert |
| 11/21/2022 | Buy Now | 49.07% | Piper Sandler | Joseph Catanzaro | $13 → $11 | Maintains | Neutral | Get Alert |
| 11/21/2022 | Buy Now | 292.99% | Chardan Capital | Geulah Livshits | $30 → $29 | Maintains | Buy | Get Alert |
| 11/18/2022 | Buy Now | 414.95% | HC Wainwright & Co. | Joseph Pantginis | $43 → $38 | Maintains | Buy | Get Alert |
| 10/31/2022 | Buy Now | — | Guggenheim | Kelsey Goodwin | — | Initiates | → Neutral | Get Alert |
| 08/10/2022 | Buy Now | 225.23% | Stifel | Benjamin Burnett | → $24 | Maintains | Buy | Get Alert |
| 08/05/2022 | Buy Now | 238.79% | Baird | Michael Ulz | $34 → $25 | Maintains | Outperform | Get Alert |
| 07/01/2022 | Buy Now | 143.93% | Goldman Sachs | Madhu Kumar | $64 → $18 | Maintains | Buy | Get Alert |
| 05/27/2022 | Buy Now | 76.17% | Stifel | Benjamin Burnett | $26 → $13 | Maintains | Buy | Get Alert |
| 05/27/2022 | Buy Now | 265.89% | Oppenheimer | Mark Breidenbach | $31 → $27 | Maintains | Outperform | Get Alert |
| 05/27/2022 | Buy Now | 320.09% | Chardan Capital | Geulah Livshits | $44 → $31 | Maintains | Buy | Get Alert |
| 05/27/2022 | Buy Now | 76.17% | Piper Sandler | Joseph Catanzaro | $20 → $13 | Maintains | Neutral | Get Alert |
| 05/24/2022 | Buy Now | 767.29% | Goldman Sachs | Madhu Kumar | $79 → $64 | Maintains | Buy | Get Alert |
| 05/06/2022 | Buy Now | 252.34% | Stifel | Benjamin Burnett | → $26 | Maintains | Buy | Get Alert |
| 04/07/2022 | Buy Now | 360.75% | Baird | Colleen Kusy | $30 → $34 | Maintains | Outperform | Get Alert |
| 02/25/2022 | Buy Now | 306.54% | Baird | Colleen Kusy | $35 → $30 | Maintains | Outperform | Get Alert |
| 02/25/2022 | Buy Now | 509.81% | Chardan Capital | Geulah Livshits | $50 → $45 | Maintains | Buy | Get Alert |
| 01/28/2022 | Buy Now | 238.79% | Stifel | Benjamin Burnett | $23 → $25 | Upgrade | Hold → Buy | Get Alert |
| 11/05/2021 | Buy Now | 482.71% | HC Wainwright & Co. | Joseph Pantginis | $46 → $43 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Iovance Biotherapeutics (IOVA) stock?
The latest price target for Iovance Biotherapeutics (NASDAQ:IOVA) was reported by HC Wainwright & Co. on June 28, 2024. The analyst firm set a price target for $32.00 expecting IOVA to rise to within 12 months (a possible 333.65% upside). 37 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Iovance Biotherapeutics (IOVA)?
The latest analyst rating for Iovance Biotherapeutics (NASDAQ:IOVA) was provided by HC Wainwright & Co., and Iovance Biotherapeutics reiterated their buy rating.
When was the last upgrade for Iovance Biotherapeutics (IOVA)?
The last upgrade for Iovance Biotherapeutics Inc happened on May 30, 2023 when Wells Fargo raised their price target to $17. Wells Fargo previously had an equal-weight for Iovance Biotherapeutics Inc.
When was the last downgrade for Iovance Biotherapeutics (IOVA)?
The last downgrade for Iovance Biotherapeutics Inc happened on December 9, 2022 when Goldman Sachs changed their price target from $20 to $6 for Iovance Biotherapeutics Inc.
When is the next analyst rating going to be posted or updated for Iovance Biotherapeutics (IOVA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Iovance Biotherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Iovance Biotherapeutics was filed on June 28, 2024 so you should expect the next rating to be made available sometime around June 28, 2025.
Is the Analyst Rating Iovance Biotherapeutics (IOVA) correct?
While ratings are subjective and will change, the latest Iovance Biotherapeutics (IOVA) rating was a reiterated with a price target of $32.00 to $32.00. The current price Iovance Biotherapeutics (IOVA) is trading at is $7.38, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.